[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100592476":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":31,"centralContacts":32,"locations":38,"responsibleParty":61,"collaborators":31,"id":65,"slug":66,"hasResults":67,"nctId":68,"briefTitle":69,"officialTitle":69,"acronym":31,"eligibilityCriteria":70,"healthyVolunteers":67,"sex":71,"minAge":72,"maxAge":73,"enrollmentInfo":74,"targetDuration":31,"studyType":77,"phases":78,"briefSummary":80,"conditions":81,"keywords":31,"overallStatus":40,"whyStopped":31,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":91,"completionDateStruct":92,"leadSponsor":94,"locationsCount":95},{"fullName":5,"class":6},"Ain Shams University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Group SB","ACTIVE_COMPARATOR","Patients will receive a scalp block with bupivacaine alone.",[13],"Other: Scalp block",{"label":15,"type":16,"description":17,"interventionNames":18},"Group SD","EXPERIMENTAL","Patients will receive a scalp block with dexmedetomidine as an adjuvant to bupivacaine.",[19],"Other: Scalp block + Dexmedetomidine",[21,26],{"type":6,"name":22,"description":11,"armGroupLabels":23,"otherNames":24},"Scalp block",[9],[25],"Bupivacaine",{"type":6,"name":27,"description":17,"armGroupLabels":28,"otherNames":29},"Scalp block + Dexmedetomidine",[15],[30],"Bupivacaine + Dexmedetomidine",null,[33],{"name":34,"role":35,"phone":36,"phoneExt":31,"email":37},"Omar A Khiralla, MBBCH","CONTACT","00201095281838","Omar-Ahmed@med.asu.edu.eg",[39],{"facility":5,"status":40,"city":41,"state":31,"zip":42,"country":43,"countryCode":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":51},"RECRUITING","Cairo","11591","Egypt","EG",{"type":46,"coordinates":47},"Point",[48,49],31.24967,30.06263,{"lat":49,"lon":48},[52,54,57,59],{"name":53,"role":35,"phone":36,"phoneExt":31,"email":37},"Omar A Khiralla, Master",{"name":55,"role":56,"phone":31,"phoneExt":31,"email":31},"Hanaa M AbdAllah, MD","SUB_INVESTIGATOR",{"name":58,"role":56,"phone":31,"phoneExt":31,"email":31},"Ahmed A Khalifa, MD",{"name":60,"role":56,"phone":31,"phoneExt":31,"email":31},"Mohamed M Hashem, MD",{"type":62,"investigatorFullName":63,"investigatorTitle":64,"investigatorAffiliation":5,"oldNameTitle":31,"oldOrganization":31},"PRINCIPAL_INVESTIGATOR","Omar Ahmed Zakaria Khiralla","Resident of Anaesthesia, Intensive Care Unit and Pain, Faculty of Medicine, Ain shams University, Cairo, Egypt.","100592476","dexmedetomidine-as-an-adjuvant-to-bupivacaine-in-scalp-block-versus-bupivacaine-alone-for-postoperative-pain-management-in-patients-undergoing-craniotomy-100592476",false,"NCT06993922","Dexmedetomidine as an Adjuvant to Bupivacaine in Scalp Block Versus Bupivacaine Alone for Postoperative Pain Management in Patients Undergoing Craniotomy","Inclusion Criteria:\n\n* Age from 18 to 65 years.\n* Both sexes.\n* American Society of Anesthesiologists (ASA) physical status I or II.\n* Undergoing supratentorial elective planned craniotomies.\n\nExclusion Criteria:\n\n* Patients refusal.\n* History of known allergy to the used local anesthetic or dexmedetomidine.\n* Bleeding disorders.\n* Evidence of local infection at the site of injection.\n* Emergency craniotomy.\n* Psychotic disorder.\n* Patients who will not be extubated in the operating room after surgery.","ALL","18 Years","65 Years",{"count":75,"type":76},50,"ESTIMATED","INTERVENTIONAL",[79],"NA","This study aims to compare dexmedetomidine as an adjuvant to bupivacaine in scalp block versus bupivacaine alone for postoperative pain management in patients undergoing craniotomy.",[82,83,25,84,85,86],"Dexmedetomidine","Adjuvant","Scalp Block","Postoperative Pain","Craniotomy","2025-05-29",{"date":89,"type":90},"2025-05-30","ACTUAL",{"date":87,"type":90},{"date":93,"type":76},"2025-11-01",{"name":5,"class":6},1]